{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:27:54Z","timestamp":1767144474130,"version":"build-2238731810"},"update-to":[{"DOI":"10.1016\/j.canlet.2019.05.028","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000}}],"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.canlet.2019.05.028","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T12:00:43Z","timestamp":1558612843000},"page":"29-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["RETRACTED: IP1867B suppresses the Insulin-like Growth Factor 1 Receptor (IGF1R) ablating Epidermal Growth Factor Receptor inhibitor resistance in adult high grade gliomas"],"prefix":"10.1016","volume":"458","author":[{"given":"K.","family":"Mihajluk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Simms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Reay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.A.","family":"Madureira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.","family":"Duckworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.J.","family":"Pilkington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2019.05.028_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.canlet.2019.05.028_bib2","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1016\/S1470-2045(17)30345-5","article-title":"European Association of Neuro-Oncology palliative care task force, European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma","volume":"18","author":"Pace","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.05.028_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.05.028_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"European organisation for Research and treatment of cancer brain tumor and radiotherapy groups, National cancer institute of Canada clinical trials group, radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.05.028_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00001813-199902000-00006","article-title":"Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide","volume":"10","author":"Sankar","year":"1999","journal-title":"Anti Canccer Drugs"},{"key":"10.1016\/j.canlet.2019.05.028_bib6","first-page":"2933","article-title":"Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft","volume":"57","author":"Friedman","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.05.028_bib7","first-page":"3793","article-title":"Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea","volume":"54","author":"Plowman","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.05.028_bib8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2002.20.5.1375","article-title":"Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide","volume":"20","author":"Stupp","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.05.028_bib9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.05.028_bib10","article-title":"Drug repurposing: progress, challenges and recommendations","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2019.05.028_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13046-017-0642-x","article-title":"Drug repurposing for the treatment of glioblastoma multiforme","volume":"36","author":"Abbruzzese","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.05.028_bib12","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3390\/ijms19092768","article-title":"Drug repurposing of metabolic agents in malignant glioma","volume":"19","author":"Seliger","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2019.05.028_bib13","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","article-title":"Anti-inflammatory agents: present and future","volume":"140","author":"Dinarello","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2019.05.028_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccr.2005.02.013","article-title":"Smoldering and polarized inflammation in the initiation and promotion of malignant disease","volume":"7","author":"Balkwill","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2019.05.028_bib15","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2009.22.7918","article-title":"Aspirin intake and survival after breast cancer","volume":"28","author":"Holmes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.05.028_bib16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/s41431-018-0197-0","article-title":"Cancer prevention by aspirin in children with constitutional mismatch repair deficiency (CMMRD)","volume":"26","author":"Leenders","year":"2018","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.canlet.2019.05.028_bib17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.2009.1112","article-title":"Aspirin use and survival after diagnosis of colorectal cancer","volume":"302","author":"Chan","year":"2009","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.canlet.2019.05.028_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ccr.2013.09.017","article-title":"EGFR and EGFRvIII in glioblastoma: partners in crime","volume":"24","author":"Zadeh","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2019.05.028_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1479-5876-3-38","article-title":"The natural history of EGFR and EGFRvIII in glioblastoma patients","volume":"3","author":"Heimberger","year":"2005","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2019.05.028_bib20","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","article-title":"A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity","volume":"91","author":"Nishikawa","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2019.05.028_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2019.05.028_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/neuonc\/nov096","article-title":"Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation","volume":"18","author":"Gong","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2019.05.028_bib23","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1158\/1078-0432.CCR-15-1677","article-title":"InsR\/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma","volume":"22","author":"Ma","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.05.028_bib24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.canlet.2019.05.028_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccr.2013.06.017","article-title":"Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can Be targeted therapeutically","volume":"24","author":"Putoczki","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2019.05.028_bib26","article-title":"Abstract 186: FDA approved drug Bazedoxifene as a novel inhibitor of IL 6 and IL 11\/GP130 signaling for osteosarcoma therapy","volume":"77","author":"Wu","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.05.028_bib27","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.37161","article-title":"The SERM\/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells","volume":"7","author":"Fanning","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.canlet.2019.05.028_bib28","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1158\/1078-0432.CCR-15-1677","article-title":"InsR\/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma","volume":"22","author":"Ma","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.05.028_bib29","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ccr.2013.09.004","article-title":"EGFR phosphorylates tumor-derived EGFRvIII driving STAT3\/5 and progression in glioblastoma","volume":"24","author":"Fan","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2019.05.028_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrurol.2011.219","article-title":"Aspirin and urologic cancer risk: an update","volume":"9","author":"Bosetti","year":"2012","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2019.05.028_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bbcan.2016.08.002","article-title":"Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials","volume":"1866","author":"Jiang","year":"2016","journal-title":"Biochim. Biophys. Acta Rev. Canc."},{"key":"10.1016\/j.canlet.2019.05.028_bib32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","article-title":"Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement","volume":"10","author":"Cuzick","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2019.05.028_bib33","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamaoncol.2015.6396","article-title":"Population-wide impact of long-term use of aspirin and the risk for cancer","volume":"2","author":"Cao","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canlet.2019.05.028_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cpcardiol.2017.01.006","article-title":"Upper gastrointestinal toxicity associated with long-term aspirin therapy: consequences and prevention","volume":"42","author":"Lavie","year":"2017","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.canlet.2019.05.028_bib35","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1002\/cncr.21539","article-title":"A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999","volume":"104","author":"Chakrabarti","year":"2005","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.canlet.2019.05.028_bib36","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2019.05.028_bib37","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1517\/13543784.2012.703177","article-title":"Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions","volume":"21","author":"Patel","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.canlet.2019.05.028_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/156800912799277557","article-title":"Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance","volume":"12","author":"Taylor","year":"2012","journal-title":"Curr. Cancer Drug Targets"}],"updated-by":[{"DOI":"10.1016\/j.canlet.2021.03.008","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"record-id":"26802"},{"DOI":"10.1016\/j.canlet.2019.10.002","type":"correction","label":"Correction","source":"retraction-watch","updated":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"record-id":"26803"},{"DOI":"10.1016\/j.canlet.2019.10.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000}},{"DOI":"10.1016\/j.canlet.2019.05.028","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000}},{"DOI":"10.1016\/j.canlet.2021.03.008","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000}}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519303234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519303234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:43:57Z","timestamp":1759592637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383519303234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":38,"alternative-id":["S0304383519303234"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2019.05.028","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RETRACTED: IP1867B suppresses the Insulin-like Growth Factor 1 Receptor (IGF1R) ablating Epidermal Growth Factor Receptor inhibitor resistance in adult high grade gliomas","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2019.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}